You can seek FDA approval to launch a generic drug before the expiration of ABILIFY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY:-

You can seek FDA approval to launch a generic drug before the expiration of ABILIFY MAINTENA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY MAINTENA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY MAINTENA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of CERDELGA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CERDELGA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CERDELGA:-

You can seek FDA approval to launch a generic drug before the expiration of EPIDIOLEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EPIDIOLEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EPIDIOLEX:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of HETLIOZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the HETLIOZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on HETLIOZ:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of LYNPARZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LYNPARZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LYNPARZA:-

You can seek FDA approval to launch a generic drug before the expiration of MOVANTIK's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MOVANTIK's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MOVANTIK:-

You can seek FDA approval to launch a generic drug before the expiration of OCALIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OCALIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OCALIVA:-

You can seek FDA approval to launch a generic drug before the expiration of PRISTIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PRISTIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PRISTIQ:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of SAXENDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SAXENDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SAXENDA:-

You can seek FDA approval to launch a generic drug before the expiration of TRULANCE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRULANCE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRULANCE:-

You can seek FDA approval to launch a generic drug before the expiration of VIIBRYD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIIBRYD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIIBRYD:-